X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Licensing Agreement December 05, 2023
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, which is investigated for the treatmet of moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Acquisition adds CTP‑543 (deuruxolitinib), a Potential Best-in-Class oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease which is in late-stage development, to Sun Pharma's Global Dermatology Portfolio.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition March 06, 2023
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. It has received breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Concert has an extensive patent portfolio, including its lead product candidate CTP‑543 (deuruxolitinib) – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP‑543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: $576.0 million Upfront Cash: $576.0 million
Deal Type: Acquisition January 19, 2023
Details:
Deuruxolitinib (CTP-543) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. Deuruxolitinib was generally well-tolerated in THRIVE-AA1, consistent with its other Phase 2 and Phase 3 studies.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
The presentation highlights THRIVE-AA1 study results evaluating Concert’s oral investigational medicine CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
CTP-543 (deuruxolitinib) is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2, for the treatment of adult patients with moderate to severe alopecia areata.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
The publication reports clinically meaningful and statistically significant scalp hair regrowth after 24 weeks of treatment with CTP-543 (deuruxolitinib) in both the 8 mg twice-daily and 12 mg twice-daily dose groups in patients with alopecia areata.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Concert intends to use the net proceeds from the offering, to complete clinical development supporting the filing of its NDA for CTP-543 (deuruxolitinib) for the treatment of moderate to severe alopecia areata in adults, conduct pre-commercial activities related to CTP-543.
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $47.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
